ArticleNPJ breast cancer2025

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.

Masahiro Takada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.